Psychedelic and ketamine research trials in Poland

Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.

5 registered studies are counted in Poland. By compound: 5 ketamine. By registry status: 1 enrolling by invitation and 4 completed. By phase: 2 phase 2 and 3 not reported. Reported start years run from 2019 (earliest) to 2023 (latest). Studies are linked to 2 institutions.

Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

Recruiting now

None of the 5 counted studies in Poland is listed in the registry as recruiting or not yet recruiting as of 11 October 2026. Status is reported by study teams and can be out of date.

At a glance

5 registered studies are counted on this page.

By compound

Compound hub	Studies
Ketamine	5

By registry status

Status	Studies	Share
Enrolling by invitation	1	20%
Completed	4	80%

By phase

Phase	Studies	Share
Phase 2	2	40%
Not reported	3	60%

When studies started

Start year	Studies
2020 to 2023	2
2015 to 2019	3

All counted studies

All 5 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registered	Registry ID	Status	Phase	Start	Institution and city
Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression	NCT06232291	Completed	Not reported	2023-04-21	Medical University of Gdansk, Gdansk
Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)	NCT05565352	Enrolling by invitation	Not reported	2022-09-01	Medical University of Gdansk, Gdansk
A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders	NCT04226963	Completed	Not reported	2019-12-04	Medical University of Gdansk, Gdansk
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression	NCT03965871	Completed	Phase 2	2019-03-28	Celon Pharma SA, Bełchatów
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression	NCT03965858	Completed	Phase 2	2019-02-25	Celon Pharma SA, Bełchatów

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Ketamine

Institution hubs in this country

Institutions in this country with at least 3 counted studies. The number is that institution's own count of studies, which can include studies not shown above if the registry lists them under another country.

Medical University of Gdansk: 3 studies

Condition hubs

Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.

Condition hub	Studies in this country
Depression	5
Treatment-resistant depression	4
Bipolar disorder	2
Anxiety	1
Obsessive-compulsive disorder	1

Other country hubs

All trial hubs | Learn | Disclaimer